An evidence-based review of unoprostone isopropyl ophthalmic solution 0.15% for glaucoma: place in therapy
Derrick S Fung, Jess T WhitsonDepartment of Ophthalmology, University of Texas Southwestern Medical Center, Dallas, TX, USAAbstract: Glaucoma is a progressive, neurodegenerative optic nerve disease that can cause significant visual morbidity and affects over 60 million people worldwide. The only kn...
Guardado en:
Autores principales: | Fung DS, Whitson JT |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://doaj.org/article/c0dd7ba5f4ad43eaae716b06f10dd0d7 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Latanoprostene bunod ophthalmic solution 0.024% in the treatment of open-angle glaucoma: design, development, and place in therapy
por: Addis VM, et al.
Publicado: (2018) -
Epidemiology and characteristics of childhood glaucoma: results from the Dallas Glaucoma Registry
por: Fung DS, et al.
Publicado: (2013) -
Comparative efficacy of bepotastine besilate 1.5% ophthalmic solution versus olopatadine hydrochloride 0.2% ophthalmic solution evaluated by patient preference
por: McCabe CF, et al.
Publicado: (2012) -
Twenty-Four-Hour Intraocular Pressure Control with Omidenepag Isopropyl 0.002% in Patients with Glaucoma and Ocular Hypertension
por: Shiratori N, et al.
Publicado: (2021) -
Profile of netarsudil ophthalmic solution and its potential in the treatment of open-angle glaucoma: evidence to date
por: Dasso L, et al.
Publicado: (2018)